Study Shows Roche's Perjeta Extended Lives of Breast Cancer Patients by 15.7 Months
Adding Perjeta to Herceptin and docetaxel chemotherapy extended the lives of people with previously untreated HER2-positive metastatic breast cancer (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - September 30, 2014 Category: Pharmaceuticals Source Type: news

Nintedanib receives positive CHMP opinion for second-line treatment
Nintedanib*, when added to docetaxel, is the first lung cancer treatment to have provided over one year overall survival for patients with advanced adenocarcinoma, after first-line chemotherapy.09/29/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - September 29, 2014 Category: Cancer & Oncology Source Type: news

16 Months' Longer Survival with Addition of Pertuzumab in Advanced Breast Cancer (FREE)
By Kelly Young Edited by Susan Sadoughi, MD, and André Sofair, MD, MPH Adding pertuzumab (Perjeta) to docetaxel and trastuzumab (Herceptin) as a first-line treatment was associated with … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - September 29, 2014 Category: Primary Care Source Type: news

Roche's Perjeta regimen extended the lives of people with an aggressive type of metastatic breast cancer by 15.7 months compared to Herceptin and chemotherapy
Roche today announced final survival results from the Phase III CLEOPATRA study, which showed that adding Perjeta (pertuzumab) to Herceptin (trastuzumab) and docetaxel chemotherapy extended the lives (overall survival; OS) of people with previously untreated HER2-positive metastatic breast cancer (mBC) by 15.7 months compared to Herceptin and chemotherapy (median OS: 56.5 vs. 40.8 months). (Source: Roche Media News)
Source: Roche Media News - September 28, 2014 Category: Pharmaceuticals Source Type: news

Roche's Perjeta regimen extended the lives of people with an aggressive type of metastatic breast cancer by 15.7 months compared to Herceptin and chemotherapy
Roche today announced final survival results from the Phase III CLEOPATRA study, which showed that adding Perjeta (pertuzumab) to Herceptin (trastuzumab) and docetaxel chemotherapy extended the lives (overall survival; OS) of people with previously untreated HER2-positive metastatic breast cancer (mBC) by 15.7 months compared to Herceptin and chemotherapy (median OS: 56.5 vs. 40.8 months). (Source: Roche Investor Update)
Source: Roche Investor Update - September 28, 2014 Category: Pharmaceuticals Source Type: news

Docetaxel or pemetrexed with cisplatin achieve comparable outcomes in non-squamous Lu Ca
(European Society for Medical Oncology) The first direct comparison of treating non-squamous lung cancer with either pemetrexed or docetaxel in addition to cisplatin has shown that the two combinations achieve similar progression-free survival, although docetaxel was associated with more frequent adverse events. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - September 27, 2014 Category: Biology Source Type: news

HER2 in Trastuzumab/Emtansine vs Trastuzumab/DocetaxelHER2 in Trastuzumab/Emtansine vs Trastuzumab/Docetaxel
What group of patients experience enhanced improvement from T-DM1 therapy? Breast Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 19, 2014 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

FDA Warning on Symptoms of Alcohol Intoxication from Docetaxel:...
On June 20, the FDA issued a warning that Docetaxel may cause intoxication. In light of this news, AttorneyOne, a recognized authority on law, updated the website providing detailed information to...(PRWeb June 24, 2014)Read the full story at http://www.prweb.com/releases/2014/06/prweb11965384.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - June 24, 2014 Category: Pharmaceuticals Source Type: news

FDA warns docetaxel may cause symptoms of alcohol intoxication after treatment
Read the full story on MD Consult: FDA warns docetaxel may cause symptoms of alcohol intoxication after treatment (Source: MD Consult: News: Top Stories)
Source: MD Consult: News: Top Stories - June 24, 2014 Category: Journals (General) Source Type: news

Can Cancer Patients Really Get 'Drunk' From Docetaxel?
Well, yes and no. The calculated amount of ethanol in a typical dose is no more than a few sips of beer and I was initially compelled to pooh-pooh FDA's warning. But even that amount of alcohol can be disorienting to patients on other medicines, or those having other issues where they might not expect such a feeling. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - June 23, 2014 Category: Pharmaceuticals Authors: David Kroll Source Type: news

Chemo Drug May Cause Patients to Feel Drunk (FREE)
By Kristin J. Kelley Edited by Susan Sadoughi, MD, and Jaye Elizabeth Hefner, MD Ethanol in the cancer drug docetaxel may cause patients to feel … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - June 23, 2014 Category: Primary Care Source Type: news

FDA Warns of Docetaxel Alcohol Risk
WASHINGTON (MedPage Today) -- Oncologists who prescribe docetaxel for cancer patients should pay attention to intoxication-like symptoms the drug can cause, according to a safety communication from the FDA. (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - June 20, 2014 Category: American Health Source Type: news

Docetaxel: Drug Safety Communication - May Cause Symptoms of Alcohol Intoxication
Docetaxel contains alcohol, which affects the central nervous system. (Source: FDA MedWatch)
Source: FDA MedWatch - June 20, 2014 Category: American Health Source Type: news

Cancer Patients May 'Feel Drunk' From Docetaxel, Says FDACancer Patients May 'Feel Drunk' From Docetaxel, Says FDA
The intravenous chemotherapy contains alcohol and might result in intoxication; the federal agency is revising the drug label to include this risk. News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 20, 2014 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news